Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Survival in patients with malignant pleural effusion undergoing talc pleurodesis.

Hassan M, Mercer RM, Maskell NA, Asciak R, McCracken DJ, Bedawi EO, Shaarawy H, El-Ganady A, Psallidas I, Miller RF, Rahman NM.

Lung Cancer. 2019 Sep 4;137:14-18. doi: 10.1016/j.lungcan.2019.09.003. [Epub ahead of print]

PMID:
31521977
2.

Reply to G. Zalcman et al.

Bayman N, Clive A, Maskell N, Ryder D, Taylor H, Faivre-Finn C.

J Clin Oncol. 2019 Aug 22:JCO1901520. doi: 10.1200/JCO.19.01520. [Epub ahead of print] No abstract available.

PMID:
31437093
3.

Inter-observer variation in image interpretation and the prognostic importance of non-expansile lung in malignant pleural effusion.

Martin GA, Kidd AC, Tsim S, Halford P, Bibby A, Maskell NA, Blyth KG.

Respirology. 2019 Aug 21. doi: 10.1111/resp.13681. [Epub ahead of print]

PMID:
31433545
4.

Epstein-Barr virus in pleural effusions: protagonist or pretender?

Arnold DT, Suri T, Hamilton F, Morley A, Medford A, Vipond IB, Muir P, Maskell NA.

Eur Respir J. 2019 Jun 27. pii: 1900825. doi: 10.1183/13993003.00825-2019. [Epub ahead of print] No abstract available.

PMID:
31248955
5.

Primary spontaneous pneumothorax: time for surgery at first episode?

Cardillo G, Ricciardi S, Rahman N, Walker S, Maskell NA.

J Thorac Dis. 2019 May;11(Suppl 9):S1393-S1397. doi: 10.21037/jtd.2019.03.22. No abstract available.

6.

The Prevalence and Clinical Relevance of Non-expandable Lung in Malignant Pleural Mesothelioma: A Prospective, Single-Center Cohort Study of 229 Patients.

Bibby AC, Halford P, De Fonseka D, Morley AJ, Smith S, Maskell NA.

Ann Am Thorac Soc. 2019 Jun 12. doi: 10.1513/AnnalsATS.201811-786OC. [Epub ahead of print]

PMID:
31189069
7.

Imaging for malignant pleural effusions-still no routine role of positron emission tomography.

Arnold DT, Maskell N.

J Thorac Dis. 2019 Apr;11(4):1079-1081. doi: 10.21037/jtd.2019.02.99. No abstract available.

8.

The use of indwelling pleural catheters for the treatment of malignant pleural effusions.

Syer T, Walker S, Maskell N.

Expert Rev Respir Med. 2019 Jul;13(7):659-664. doi: 10.1080/17476348.2019.1627203. Epub 2019 Jun 19.

PMID:
31177915
9.

Development of and Gathering Validity Evidence for a Theoretical Test in Thoracic Ultrasound.

Pietersen PI, Konge L, Madsen KR, Bendixen M, Maskell NA, Rahman N, Graumann O, Laursen CB.

Respiration. 2019;98(3):221-229. doi: 10.1159/000500146. Epub 2019 May 28.

PMID:
31137031
10.

Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial.

Luengo-Fernandez R, Penz E, Dobson M, Psallidas I, Nunn AJ, Maskell NA, Rahman NM.

Eur Respir J. 2019 Aug 1;54(2). pii: 1801550. doi: 10.1183/13993003.01550-2018. Print 2019 Aug.

PMID:
31097519
11.

The International Collaborative Effusion (ICE) database: an ERS Clinical Research Collaboration.

Bhatnagar R, Janssen J, Maskell N.

Eur Respir J. 2019 May 2;53(5). pii: 1900591. doi: 10.1183/13993003.00591-2019. Print 2019 May. No abstract available.

PMID:
31048373
12.

Outpatient talc administration via indwelling pleural catheters for malignant effusions.

Dipper A, Bhatnagar R, Maskell N.

Curr Opin Pulm Med. 2019 Jul;25(4):380-383. doi: 10.1097/MCP.0000000000000587.

PMID:
30998600
13.

Relationship of pleural fluid pH and glucose: a multi-centre study of 2,971 cases.

Fitzgerald DB, Leong SL, Budgeon CA, Murray K, Rosenstengal A, Smith NA, Bielsa S, Clive AO, Maskell NA, Porcel JM, Lee YCG.

J Thorac Dis. 2019 Jan;11(1):123-130. doi: 10.21037/jtd.2018.12.101.

14.

Is pleural infection associated with longer survival in mesothelioma? A population-based cohort study using data from Hospital Episode Statistics.

Bibby AC, de Fonseka D, Carslake DJ, Maskell NA.

Cancer Epidemiol. 2019 Apr;59:75-82. doi: 10.1016/j.canep.2019.01.014. Epub 2019 Jan 30.

15.

MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.

Matthews C, Freeman C, Sharples LD, Fox-Rushby J, Tod A, Maskell NA, Edwards JG, Coonar AS, Sivasothy P, Hughes V, Rahman NM, Waller DA, Rintoul RC.

BMJ Open Respir Res. 2019 Jan 5;6(1):e000368. doi: 10.1136/bmjresp-2018-000368. eCollection 2019.

16.

Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial.

Brims F, Gunatilake S, Lawrie I, Marshall L, Fogg C, Qi C, Creech L, Holtom N, Killick S, Yung B, Cooper D, Stadon L, Cook P, Fuller E, Walther J, Plunkett C, Bates A, Mackinlay C, Tandon A, Maskell NA, Forbes K, Rahman NM, Gerry S, Chauhan AJ; RESPECT-Meso investigators.

Thorax. 2019 Apr;74(4):354-361. doi: 10.1136/thoraxjnl-2018-212380. Epub 2019 Jan 19.

PMID:
30661019
17.

Checkpoint inhibitors in mesothelioma: hope for the future?

Bibby A, Maskell N.

Lancet Oncol. 2019 Feb;20(2):172-174. doi: 10.1016/S1470-2045(18)30868-4. Epub 2019 Jan 16. No abstract available.

PMID:
30660608
18.

Summary for Clinicians: Clinical Practice Guideline for Management of Malignant Pleural Effusions.

Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YCG, Lewis SZ, Maskell NA, Rahman NM, Sterman DH, Wahidi MM, Balekian AA, Feller-Kopman DJ.

Ann Am Thorac Soc. 2019 Jan;16(1):17-21. doi: 10.1513/AnnalsATS.201809-620CME. No abstract available.

PMID:
30516394
19.

Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline.

Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YCG, Lewis SZ, Maskell NA, Rahman NM, Sterman DH, Wahidi MM, Balekian AA.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):839-849. doi: 10.1164/rccm.201807-1415ST.

PMID:
30272503
20.

Investigating unilateral pleural effusions: the role of cytology.

Arnold DT, De Fonseka D, Perry S, Morley A, Harvey JE, Medford A, Brett M, Maskell NA.

Eur Respir J. 2018 Nov 8;52(5). pii: 1801254. doi: 10.1183/13993003.01254-2018. Print 2018 Nov.

PMID:
30262573
21.

Local Anaesthetic (Medical) Thoracoscopy Services in the UK.

de Fonseka D, Bhatnagar R, Maskell NA.

Respiration. 2018;96(6):560-563. doi: 10.1159/000491674. Epub 2018 Sep 10.

PMID:
30199872
22.

Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.

de Fonseka D, Morley A, Stadon L, Keenan E, Walker S, Smith S, Harvey JE, Cox RA, Dangoor A, Comins C, Rogers C, Edey A, Addeo A, Maskell NA.

Trials. 2018 Aug 29;19(1):467. doi: 10.1186/s13063-018-2851-9.

23.

Current treatments and trials in malignant pleural mesothelioma.

Bibby AC, Maskell NA.

Clin Respir J. 2018 Jul;12(7):2161-2169. doi: 10.1111/crj.12938. Review.

PMID:
30129116
24.

Providing safe and effective pleural medicine services in the UK: an aspirational statement from UK pleural physicians.

Evison M, Blyth KG, Bhatnagar R, Corcoran J, Saba T, Duncan T, Hallifax R, Ahmed L, West A, Pepperell JCT, Roberts M, Sivasothy P, Psallidas I, Clive AO, Latham J, Stanton AE, Maskell N, Rahman N.

BMJ Open Respir Res. 2018 Aug 3;5(1):e000307. doi: 10.1136/bmjresp-2018-000307. eCollection 2018.

25.

ERS/EACTS statement on the management of malignant pleural effusions.

Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Maskell NA, Cardillo G.

Eur J Cardiothorac Surg. 2019 Jan 1;55(1):116-132. doi: 10.1093/ejcts/ezy258. Review.

PMID:
30060030
26.

ERS/EACTS statement on the management of malignant pleural effusions.

Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Cardillo G, Maskell NA.

Eur Respir J. 2018 Jul 27;52(1). pii: 1800349. doi: 10.1183/13993003.00349-2018. Print 2018 Jul. Review.

PMID:
30054348
27.

Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial.

Muruganandan S, Azzopardi M, Fitzgerald DB, Shrestha R, Kwan BCH, Lam DCL, De Chaneet CC, Rashid Ali MRS, Yap E, Tobin CL, Garske LA, Nguyen PT, Stanley C, Popowicz ND, Kosky C, Thomas R, Read CA, Budgeon CA, Feller-Kopman D, Maskell NA, Murray K, Lee YCG.

Lancet Respir Med. 2018 Sep;6(9):671-680. doi: 10.1016/S2213-2600(18)30288-1. Epub 2018 Jul 20.

PMID:
30037711
28.

Are intra-pleural bacterial products associated with longer survival in adults with malignant pleural effusions? A systematic review.

Bibby AC, Walker S, Maskell NA.

Lung Cancer. 2018 Aug;122:249-256. doi: 10.1016/j.lungcan.2018.06.002. Epub 2018 Jun 11.

29.

Recurrence rates in primary spontaneous pneumothorax: a systematic review and meta-analysis.

Walker SP, Bibby AC, Halford P, Stadon L, White P, Maskell NA.

Eur Respir J. 2018 Sep 6;52(3). pii: 1800864. doi: 10.1183/13993003.00864-2018. Print 2018 Sep.

PMID:
30002105
30.

Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.

Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, Schiller HB, Fischer R, Asciak R, Hallifax RJ, Mercer R, Dobson M, Dong T, Pavord ID, Collins GS, Kessler BM, Pass HI, Maskell N, Stathopoulos GT, Rahman NM.

Lancet Oncol. 2018 Jul;19(7):930-939. doi: 10.1016/S1470-2045(18)30294-8. Epub 2018 Jun 13.

PMID:
29908990
31.

An Inconvenient Truth Concerning Surgery for Mesothelioma.

de Fonseka D, Slade M, Blyth KG, Edwards J, Evison M, Roberts M, Rahman N, Woolhouse I, Maskell NA.

J Clin Oncol. 2018 Sep 10;36(26):2745-2746. doi: 10.1200/JCO.2018.78.6590. Epub 2018 Jun 14. No abstract available.

PMID:
29902107
32.

Visual analogue scales for interstitial lung disease: a prospective validation study.

Yates H, Adamali HI, Maskell N, Barratt S, Sharp C.

QJM. 2018 May 16. doi: 10.1093/qjmed/hcy102. [Epub ahead of print]

PMID:
29788503
33.

Pleuroparenchymal sarcoidosis - A recognised but rare manifestation of disease.

Walker S, Adamali H, Bhatt N, Maskell N, Barratt SL.

Respir Med Case Rep. 2018 Feb 3;23:110-114. doi: 10.1016/j.rmcr.2018.01.007. eCollection 2018.

34.

Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion.

Bhatnagar R, Keenan EK, Morley AJ, Kahan BC, Stanton AE, Haris M, Harrison RN, Mustafa RA, Bishop LJ, Ahmed L, West A, Holme J, Evison M, Munavvar M, Sivasothy P, Herre J, Cooper D, Roberts M, Guhan A, Hooper C, Walters J, Saba TS, Chakrabarti B, Gunatilake S, Psallidas I, Walker SP, Bibby AC, Smith S, Stadon LJ, Zahan-Evans NJ, Lee YCG, Harvey JE, Rahman NM, Miller RF, Maskell NA.

N Engl J Med. 2018 Apr 5;378(14):1313-1322. doi: 10.1056/NEJMoa1716883.

35.

Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial).

de Fonseka D, Underwood W, Stadon L, Rahman N, Edey A, Rogers C, Maskell NA.

BMJ Open Respir Res. 2018 Feb 19;5(1):e000270. doi: 10.1136/bmjresp-2017-000270. eCollection 2018.

36.

BTS guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

BMJ Open Respir Res. 2018 Feb 14;5(1):e000266. doi: 10.1136/bmjresp-2017-000266. eCollection 2018.

37.

The role of procalcitonin in the management of pleural infection.

de Fonseka D, Maskell NA.

Curr Opin Pulm Med. 2018 Jul;24(4):380-383. doi: 10.1097/MCP.0000000000000481. Review.

PMID:
29528854
38.

A Pilot Feasibility Study in Establishing the Role of Ultrasound-Guided Pleural Biopsies in Pleural Infection (The AUDIO Study).

Psallidas I, Kanellakis NI, Bhatnagar R, Ravindran R, Yousuf A, Edey AJ, Mercer RM, Corcoran JP, Hallifax RJ, Asciak R, Shetty P, Dong T, Piotrowska HEG, Clelland C, Maskell NA, Rahman NM.

Chest. 2018 Oct;154(4):766-772. doi: 10.1016/j.chest.2018.02.031. Epub 2018 Mar 7.

PMID:
29524388
39.

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.

de Fonseka D, Arnold DT, Stadon L, Morley A, Keenan E, Darby M, Armstrong L, Virgo P, Maskell NA.

BMC Cancer. 2018 Feb 17;18(1):199. doi: 10.1186/s12885-018-4113-3.

40.

Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma.

Woolhouse I, Maskell NA.

Thorax. 2018 Mar;73(3):210-212. doi: 10.1136/thoraxjnl-2017-211416. No abstract available.

PMID:
29444989
41.

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

Thorax. 2018 Mar;73(Suppl 1):i1-i30. doi: 10.1136/thoraxjnl-2017-211321. No abstract available.

PMID:
29444986
42.

Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial.

Stewart SA, Clive AO, Maskell NA, Penz E.

PLoS One. 2018 Feb 5;13(2):e0190257. doi: 10.1371/journal.pone.0190257. eCollection 2018.

43.

Commentary: considerations for using the 'Trials within Cohorts' design in a clinical trial of an investigational medicinal product.

Bibby AC, Torgerson DJ, Leach S, Lewis-White H, Maskell NA.

Trials. 2018 Jan 8;19(1):18. doi: 10.1186/s13063-017-2432-3.

44.

18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.

Hall DO, Hooper CE, Searle J, Darby M, White P, Harvey JE, Braybrooke JP, Maskell NA, Masani V, Lyburn ID.

Nucl Med Commun. 2018 Feb;39(2):161-170. doi: 10.1097/MNM.0000000000000789.

PMID:
29300270
45.

Pneumothorax management-chest drain or needle aspiration?

Walker SP, Maskell N.

J Thorac Dis. 2017 Oct;9(10):3463-3464. doi: 10.21037/jtd.2017.08.155. No abstract available.

46.

Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study.

Bibby AC, De Fonseka D, Morley AJ, Keenan E, Addeo A, Smith S, Edey AJ, Maskell NA.

BMC Palliat Care. 2017 Dec 8;16(1):71. doi: 10.1186/s12904-017-0255-3.

47.

A Prospective Study to Evaluate a Diagnostic Algorithm for the Use of Fluid Lymphocyte Subset Analysis in Undiagnosed Unilateral Pleural Effusions.

Dixon G, Bhatnagar R, Zahan-Evans N, Clive AO, Virgo PF, Brett MT, Otton SH, Medford ARL, Maskell NA.

Respiration. 2018;95(2):98-105. doi: 10.1159/000481290. Epub 2017 Nov 10.

48.

Benign pleural schwannoma presenting with a large, blood-stained pleural effusion.

Bibby AC, Daly R, Internullo E, Edey AJ, Maskell NA.

Thorax. 2018 May;73(5):497-498. doi: 10.1136/thoraxjnl-2017-211102. Epub 2017 Nov 9. No abstract available.

PMID:
29123017
49.

Conservative Management in Traumatic Pneumothoraces: An Observational Study.

Walker SP, Barratt SL, Thompson J, Maskell NA.

Chest. 2018 Apr;153(4):946-953. doi: 10.1016/j.chest.2017.10.015. Epub 2017 Nov 15.

PMID:
29080710
50.

Biomarkers in mesothelioma.

Arnold DT, Maskell NA.

Ann Clin Biochem. 2018 Jan;55(1):49-58. doi: 10.1177/0004563217741145. Epub 2017 Nov 13. Review.

PMID:
29058958

Supplemental Content

Loading ...
Support Center